Stock MRNS MARINUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
1.33 USD -3.97% Intraday chart for Marinus Pharmaceuticals, Inc. -11.92% -87.76%
05-08 Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M MT
05-08 Marinus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M
MT
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024
CI
Sector Update: Health Care Stocks Softer Late Afternoon
MT
Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial
CI
Marinus Pharmaceuticals Q4 Net Loss Wider Than Expected While Revenue Misses Forecast; Shares Drop Premarket
MT
Marinus Pharmaceuticals Q4 Net Loss Narrows, Revenue Higher; Shares Plunge After-Hours
MT
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Posts Q4 Revenue $7.2M, vs. Street Est of $8.1M
MT
Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024
CI
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Marinus Pharmaceuticals Raises 2023 Product Revenue Expectation
MT
Marinus Pharmaceuticals, Inc. Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results from the Second Generation Formulation MAD Study
CI
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Posts Q3 Revenue $7.3M, vs. Street Est of $6.3M
MT
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023
CI
Marinus Pharmaceuticals, Inc. Initiates Global Access Program for ZTALMY(R) Oral Suspension CV
CI
Marinus Pharmaceuticals, Inc. Provides Revenue Guidance for 2023
CI
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q2 Revenue $6.1M, vs. Street Est of $5.7M
MT
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRNS Stock
  4. News Marinus Pharmaceuticals, Inc.
  5. Highlights